Organizational Development and Culture

The first edition of "Connecting the Dots" was published on September 29, 2017. Since Sue Nemetz penned that inaugural piece, 12 authors from our team have contributed their insight, experience, and perspective on the biopharma industry.

Credibility is essential for leaders in any industry, but in the high-stakes world of pharma and biotech, it is even more critical.

Three notable transitions worthy of reflection at this point in time.

Rare Disease Day unites this wide range of conditions under one shared umbrella, fostering a global community that amplifies the collective voice.

Reflecting on the basics of gratitude can help us find perspective and appreciate the good in our lives.

Reflecting on my career and the significant societal and technological shifts during those years, I see it as split between two generations, each half so different from the other.

This past December, the FDA finalized its guidance on rare diseases with the publication Rare Diseases: Considerations for the Development of Drugs and Biological Products. This FDA guidance has been in draft form since 2019.

I grew up in the Midwest — the middle child in a large family. We were each tagged with certain labels and expectations: the smart ones, the overachievers, and the ones still trying to find themselves (and that was before it was fashionable).

In this post-COVID era, our clients have experienced a culture shift — driven by remote work, digital transformation, accelerated innovation, and a focus on employee well-being. Changes in supply chain, clinical trials, and regulatory dynamics have accentuated all of this.